Alaunos Therapeutics, Inc.

Based in Houston, Texas, Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing cell therapies and small molecules to address oncology, obesity, and metabolic disorders. The company's pipeline includes an oral obesity compound designed to provide an alternative to injectable GLP-1 receptor agonists, with a stated emphasis on preserving lean muscle mass during treatment. Additionally, Alaunos evaluates compounds designated ALN1001 and related derivatives for their effects on lipid deposition and gene expression profiles.

The company has developed the hunTR TCR discovery platform, a technology intended to identify and target driver mutations in cancer cells. This platform represents a core component of its oncology-focused research efforts. Alaunos was incorporated in Delaware and founded in 2003, positioning it within the clinical development stage of therapeutics commercialization.

The company operates as a minimal-scale operation with one full-time employee listed on record, indicating an early or substantially scaled-back operational structure. As a Nasdaq-listed entity, Alaunos maintains public market access despite its limited headcount, suggesting reliance on external partnerships, contractors, or inactive status for its research and development activities.